Cargando…

Overcoming negative predictions of microRNA expressions to gemcitabine response with FOLFIRINOX in advanced pancreatic cancer patients

FOLFIRINOX is superior to gemcitabine in patients with pancreatic cancer, but this regimen is associated with toxicity and biomarkers for response are warranted. MicroRNAs can mediate drug resistance and could provide predictive information. Altered expressions of several microRNAs including miR-21-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schlick, Konstantin, Hohla, Florian, Hamacher, Frank, Hackl, Hubert, Hufnagl, Clemens, Markus, Steiner, Magnes, Teresa, Gampenrieder, Simon Peter, Melchardt, Thomas, Stättner, Stefan, Hauser-Kronberger, Cornelia, Greil, Richard, Rinnerthaler, Gabriel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Future Science Ltd 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7787156/ https://www.ncbi.nlm.nih.gov/pubmed/33437513 http://dx.doi.org/10.2144/fsoa-2020-0128

Ejemplares similares

Low Expression of miR-20a-5p Predicts Benefit to Bevacizumab in Metastatic Breast Cancer Patients Treated within the TANIA Phase III Trial
por: Rinnerthaler, Gabriel, et al.
Publicado: (2020)

miR-16-5p Is a Stably-Expressed Housekeeping MicroRNA in Breast Cancer Tissues from Primary Tumors and from Metastatic Sites
por: Rinnerthaler, Gabriel, et al.
Publicado: (2016)

DNA Methylation Signatures Predicting Bevacizumab Efficacy in Metastatic Breast Cancer
por: Gampenrieder, Simon Peter, et al.
Publicado: (2018)

Novel models for prediction of benefit and toxicity with FOLFIRINOX treatment of pancreatic cancer using clinically available parameters
por: Schlick, Konstantin, et al.
Publicado: (2018)

Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: results of a phase II trial (AGMT MBC-6)
por: Rinnerthaler, Gabriel, et al.
Publicado: (2021)

Spatial Heterogeneity in Large Resected Diffuse Large B-Cell Lymphoma Bulks Analysed by Massively Parallel Sequencing of Multiple Synchronous Biopsies
por: Magnes, Teresa, et al.
Publicado: (2021)

Correction: The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximab
por: Magnes, T., et al.
Publicado: (2019)

Impact of antibiotic treatment on immune-checkpoint blockade efficacy in advanced non-squamous non-small cell lung cancer
por: Huemer, Florian, et al.
Publicado: (2018)

C-Reactive Protein and Neutrophil/Lymphocytes Ratio: Prognostic Indicator for Doubling Overall Survival Prediction in Pancreatic Cancer Patients
por: Schlick, Konstantin, et al.
Publicado: (2019)

Clonal evolution in relapsed and refractory diffuse large B-cell lymphoma is characterized by high dynamics of subclones
por: Melchardt, Thomas, et al.
Publicado: (2016)

Liver toxicity during temozolomide chemotherapy caused by Chinese herbs
por: Melchardt, Thomas, et al.
Publicado: (2014)

Prognostic and Predictive Factors in Advanced Head and Neck Squamous Cell Carcinoma
por: Magnes, Teresa, et al.
Publicado: (2021)

Postoperative chemoradiotherapy with cisplatin is superior to radioimmunotherapy with cetuximab and radiotherapy alone: Analysis of the Austrian head and neck cancer registry of the AGMT
por: Magnes, Teresa, et al.
Publicado: (2021)

Comparison of gemcitabine plus oxaliplatin versus gemcitabine plus nab‐paclitaxel as first‐line chemotherapy for advanced pancreatic adenocarcinoma: A single‐center retrospective analysis
por: Schlick, Konstantin, et al.
Publicado: (2023)

Baseline Absolute Lymphocyte Count and ECOG Performance Score Are Associated with Survival in Advanced Non-Small Cell Lung Cancer Undergoing PD-1/PD-L1 Blockade
por: Huemer, Florian, et al.
Publicado: (2019)

Neoadjuvant Chemotherapy and Targeted Therapy in Breast Cancer: Past, Present, and Future
por: Gampenrieder, Simon P., et al.
Publicado: (2013)

CDK4/6 inhibition in luminal breast cancer
por: Gampenrieder, Simon Peter, et al.
Publicado: (2016)

HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer
por: Rinnerthaler, Gabriel, et al.
Publicado: (2019)

SABCS 2017: lifestyle factors, hormone receptor-positive advanced disease, liquid biopsies, and prognosis
por: Rinnerthaler, Gabriel, et al.
Publicado: (2018)

ASCO 2018 highlights: metastatic breast cancer
por: Rinnerthaler, Gabriel, et al.
Publicado: (2018)

SABCS 2016: systemic therapy for metastatic breast cancer
por: Gampenrieder, Simon Peter, et al.
Publicado: (2017)

Cytomegalovirus reactivation and its clinical impact in patients with solid tumors
por: Schlick, Konstantin, et al.
Publicado: (2015)

Anti-Hu Antibody Associated Paraneoplastic Cerebellar Degeneration in Head and Neck Cancer
por: Huemer, Florian, et al.
Publicado: (2015)

CYP39A1 polymorphism is associated with toxicity during intensive induction chemotherapy in patients with advanced head and neck cancer
por: Melchardt, Thomas, et al.
Publicado: (2015)

Clonal evolution in diffuse large B-cell lymphoma with central nervous system recurrence
por: Magnes, T., et al.
Publicado: (2021)

Update on squamous cell carcinoma of the head and neck: ASCO annual meeting 2017
por: Magnes, Teresa, et al.
Publicado: (2017)

Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie)
por: Huemer, Florian, et al.
Publicado: (2018)

Cure in metastatic breast cancer
por: Westphal, Theresa, et al.
Publicado: (2018)

Treatment Landscape for Patients with HER2-Positive Metastatic Breast Cancer: A Review on Emerging Treatment Options
por: Gampenrieder, Simon Peter, et al.
Publicado: (2020)

Prognostic score in patients with recurrent or metastatic carcinoma of the head and neck treated with cetuximab and chemotherapy
por: Magnes, Teresa, et al.
Publicado: (2017)

Comparison of gemcitabine plus nab-paclitaxel and FOLFIRINOX in metastatic pancreatic cancer
por: Han, Sung Yong, et al.
Publicado: (2020)

Combination Strategies for Immune-Checkpoint Blockade and Response Prediction by Artificial Intelligence
por: Huemer, Florian, et al.
Publicado: (2020)

Multicenter phase II trial of modified FOLFIRINOX in gemcitabine-refractory pancreatic cancer
por: Chung, Moon Jae, et al.
Publicado: (2018)

Evaluation of gemcitabine efficacy after the FOLFIRINOX regimen in patients with advanced pancreatic adenocarcinoma
por: Gilabert, Marine, et al.
Publicado: (2017)

Systemic effect of catumaxomab in a patient with metastasized colorectal cancer: a case report
por: Bezan, Angelika, et al.
Publicado: (2013)

The Role of Neutrophilic Granulocytes in Philadelphia Chromosome Negative Myeloproliferative Neoplasms
por: Kiem, Dominik, et al.
Publicado: (2021)

Radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer predicts recurrence-free survival but not pathologic complete response (pCR)
por: Gampenrieder, Simon Peter, et al.
Publicado: (2019)

Hospitalizations and Clinical Outcome in Metastatic Colorectal Cancer During Regorafenib or TAS-102 Therapy
por: Huemer, Florian, et al.
Publicado: (2020)

Folfirinox versus gemcitabine-cisplatin combination as first-line therapy in treatment of pancreaticobiliary cancer
por: KAYAHAN, Neslihan, et al.
Publicado: (2021)

Supervised versus autonomous exercise training in breast cancer patients: A multicenter randomized clinical trial
por: Westphal, Theresa, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_on2v66798d5fvl6f3sf62lv59l